JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Share price
+$72.37 (+53.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Jazz Pharmaceuticals plc grew revenue 12.6% to $4.60B over the twelve months to Jun 30, 2026. Free cash flow was $1.59B, up 25.8% from a year earlier.
Revenue
$4.60B
+12.6% vs. a year earlier
Operating income
$896.84M
TTM Q2 2026
Free cash flow
$1.59B
+25.8% vs. a year earlier
EPS, diluted
$14.62
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.47B
- P/E ratio
- 14.3
- Price to sales
- 3.14
- Price to book
- 3.01
- Dividend yield
- –
- Free cash flow yield
- 11.00%
Fundamentals
- Revenue
- $4.60B
- Net income
- $940.76M
- EPS, diluted
- $14.62
- Free cash flow
- $1.59B
- Book value per share
- $69.19
- Diluted shares
- 69M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.60B+12.6% YoY
Operating income
$896.84M
Net income
$940.76M
EPS, diluted
$14.62
Free cash flow
$1.59B+25.8% YoY
Reported periodTrailing twelve months